{"disease":{"id":"prostate-carcinoma","name":"prostate carcinoma"},"drugs":{"marketed":[{"drug_id":"jevtana","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Jevtana","company_name":"Bayer","drug_phase":"discontinued","molecular_target":"Tubulin beta","drug_class":"","quality_score":null,"revenue":"300","mechanism":""},{"drug_id":"cabazitaxel","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jevtana Kit","generic_name":"cabazitaxel","company_name":"Accord Hlthcare","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"Microtubule Inhibitor","quality_score":80,"revenue":"300","mechanism":"Cabazitaxel works by binding to tubulin beta, disrupting microtubule formation and preventing cancer cell division."},{"drug_id":"nilutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nilandron","generic_name":"NILUTAMIDE","company_name":"Advanz","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"casodex","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Casodex","company_name":"University Health Network, Toronto","drug_phase":"discontinued","molecular_target":"Cytochrome P450 2C19, Androgen receptor, Androgen receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"mitoxantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Novantrone","generic_name":"MITOXANTRONE","company_name":"","drug_phase":"marketed","molecular_target":"Serine/threonine-protein kinase pim-1","drug_class":"Topoisomerase Inhibitor","quality_score":71,"revenue":null,"mechanism":"Novantrone works by interfering with the enzyme topoisomerase, which is necessary for DNA replication and cell division."},{"drug_id":"estring","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estring","generic_name":"Estradiol","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Ovulation","drug_class":"Combined Oral Contraceptive (COC)","quality_score":71,"revenue":null,"mechanism":"Prevents pregnancy primarily by suppressing ovulation."},{"drug_id":"estradiol-cypionate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Depoestradiol","generic_name":"ESTRADIOL CYPIONATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor beta","drug_class":"Estrogen","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"bicalutamide","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Casodex","generic_name":"bicalutamide","company_name":"ANI Pharmaceuticals","drug_phase":"marketed","molecular_target":"Androgen receptor","drug_class":"Androgen Receptor Inhibitor [EPC]","quality_score":10,"revenue":null,"mechanism":"Casodex works by blocking the androgen receptor, a protein that helps prostate cancer cells grow."},{"drug_id":"mitozantrone","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Mitozantrone","company_name":"US Department of Veterans Affairs","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, ATP-binding cassette sub-family G member 2, DNA-(apurinic or apyrimidinic site) lyase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"estradiol-valerate","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Delestrogen","generic_name":"ESTRADIOL VALERATE","company_name":"Ph Health","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":65,"revenue":null,"mechanism":"Delestrogen works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."},{"drug_id":"estradiol","indication_name":"Metastatic Prostate Carcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Estrace","generic_name":"ESTRADIOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen receptor","drug_class":"Estrogen","quality_score":10,"revenue":null,"mechanism":"Estrace works by binding to estrogen receptors in the body, mimicking the effects of natural estrogen."}],"pipeline":[{"drug_id":"olaparib-oral-product","indication_name":"Advanced prostate adenocarcinoma with neuroendocrine differentiation","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Olaparib Oral Product","company_name":"Duke University","drug_phase":"discontinued","molecular_target":"PARP-1 and PARP-2 (poly-ADP-ribose polymerase enzymes)","drug_class":"PARP inhibitor (DNA repair inhibitor)","quality_score":null,"revenue":null,"mechanism":"Olaparib inhibits poly-ADP-ribose polymerase (PARP) enzymes to impair DNA repair in cancer cells with BRCA mutations or homologous recombination deficiency."}],"offLabel":[],"totalMarketed":11,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT00002540","title":"Screening for Prostate Cancer in Older Patients (PLCO Screening Trial)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":76685,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06995898","title":"The Vanguard Study: Testing a New Way to Screen for Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":6452,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03431753","title":"Early and Accurate Detection of Prostate Cancer in General Practice","phase":"NA","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT04513717","title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2753,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT03035500","title":"Long-Term Follow-Up in Patients With Prostate Cancer After Surgery","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04955808","title":"Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery","phase":"","overall_status":"SUSPENDED","enrollment_count":2400,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06773858","title":"Genetic Studies of Prostate Cancer Aggressiveness and Prognosis","phase":"","overall_status":"COMPLETED","enrollment_count":2291,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05050084","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2050,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT07484971","title":"Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Société Algérienne de Formation et Recherche en Oncologie","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07200830","title":"Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":1524,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT03396874","title":"Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1435,"lead_sponsor_name":"University of Michigan","has_results":true},{"nct_id":"NCT04254133","title":"Genetic Information to Inform Treatment and Screening for Prostate Cancer, GIFTS Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1360,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT06931340","title":"Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1260,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05946213","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1209,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT02940262","title":"Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1138,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06872619","title":"RegisterPROS - a Registry for Prostate Cancers","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1000,"lead_sponsor_name":"Wren Laboratories LLC","has_results":false},{"nct_id":"NCT04050215","title":"68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":937,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT03697148","title":"Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":852,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05931419","title":"High-Risk prostatE Cancer radiatiOn Versus surgERy","phase":"","overall_status":"RECRUITING","enrollment_count":837,"lead_sponsor_name":"Comprehensive Cancer Centre The Netherlands","has_results":false},{"nct_id":"NCT06592924","title":"Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":830,"lead_sponsor_name":"Canadian Cancer Trials Group","has_results":false},{"nct_id":"NCT04423211","title":"Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":804,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT07526545","title":"Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT06422455","title":"Access to Genetic Testing in Underserved Patients With Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT06844513","title":"Comparison Between HUGO RAS Robotic Platform and Da Vinci Robotic Platform","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":800,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03503097","title":"Genetic Testing for Men With Metastatic Prostate Cancer","phase":"","overall_status":"TERMINATED","enrollment_count":799,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06092918","title":"Generation and Validation of Predictive Models for Localized Prostate Cancer Treated With External Radiotherapy.","phase":"","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Consorci Sanitari de Terrassa","has_results":false},{"nct_id":"NCT03367702","title":"Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":692,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06029088","title":"Risk-adapted Strategy Including Magnetic Resonance Imaging and Prostate-specific Antigen Density in Blood for Biopsy Decision in Patients With Lesions Suspicious for Prostate Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":616,"lead_sponsor_name":"Ankara Etlik City Hospital","has_results":false},{"nct_id":"NCT03070886","title":"Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":612,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT06733350","title":"Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":false},{"nct_id":"NCT04134260","title":"Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":586,"lead_sponsor_name":"NRG Oncology","has_results":false},{"nct_id":"NCT04446117","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":575,"lead_sponsor_name":"Exelixis","has_results":true},{"nct_id":"NCT03860961","title":"Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy","phase":"NA","overall_status":"COMPLETED","enrollment_count":550,"lead_sponsor_name":"NRG Oncology","has_results":true},{"nct_id":"NCT06378866","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":532,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00942331","title":"Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":506,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04833517","title":"Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study)","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Universität des Saarlandes","has_results":false},{"nct_id":"NCT06946771","title":"Exploring the Correlation Between MRI Image Characteristics and Diagnosis, Pathology and Prognosis in Patients With Prostate Lesions","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Zhen Li","has_results":false},{"nct_id":"NCT04699344","title":"A Prospective, Single-centre，Single-blinded Study of PROUD for Prostate Carcinoma Diagnosis","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT03630354","title":"EXERCISING TOGETHER for Couples Coping With Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":496,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":true},{"nct_id":"NCT04220398","title":"Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":475,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT06632977","title":"Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":474,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05983432","title":"Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":470,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT04905082","title":"HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":465,"lead_sponsor_name":"City of Hope Medical Center","has_results":true},{"nct_id":"NCT06967961","title":"Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers","phase":"NA","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Institut Claudius Regaud","has_results":false},{"nct_id":"NCT04472338","title":"Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study","phase":"","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT06049355","title":"EMBRACE: Exercising Together","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT03368547","title":"68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}